Table 6. Combined summary data for clinical trials with DPP-4 inhibitor vildagliptin only and in combination with other anti-diabetic drugs.

^LegendMET: metformin. FPG: fasting plasma glucose. BID: twice daily. QD: once daily. NR: not reported. ¹ From baseline. ² Fraction of patients (in %) with HbA1c ≤ 7% at the end of the study. ³ Fraction of patients with adverse effects (in %). ⁴ Upper respiratory tract infection. ⁵ Additional adverse effect: asthenia (16.7). ^a Adjusted mean change.